Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares rose 6% on Wednesday after the company began dosing patients in a new arm of its Phase II melanoma trial, marking a key step in the development of its next-generation cancer immunotherapy.
The new cohort, part of the ongoing SCOPE study, will test intradermal delivery and a faster dosing schedule of Scancell’s iSCIB1+ Immunobody therapy in combination with checkpoint inhibitors. The company said the first eight patients were treated without significant side effects.
Earlier trial data showed encouraging results, with a disease control rate of 84% and complete response in 20% of patients.
Over 140 patients are expected to participate across four cohorts, with fresh data from the first three due in July and early findings from the new arm expected by year-end.
Scancell is also advancing its GlyMab antibody platform and plans to spin it out into a new company, Glymab Therapeutics, to sharpen its development focus.
The shares rose 0.6p to 10.37p.